SUDEEPPHRM Sudeep Pharma Q2 FY26 results (Jul–Sep 2025) and concall
Sudeep Pharma reported robust H1 FY26 performance with 31% revenue growth and 21% EBITDA growth, driven by sustained demand and strategic initiatives. The company successfully integrated the NSS acquisition, expanding its European footprint, and made significant progress in its new battery material segment with planned greenfield capex. While Q2 PAT saw a slight decline and margins compressed due to strategic investments and US tariff impacts, management expects normalization and positive reflection of these investments in subsequent quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 40.9%, net profit down 38.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 149 | 83 | 105 | 80 | 88 −41% |
| EBITDA | 63 | 26 | 45 | 30 | 31 −51% |
| Net profit | 49 | 21 | 33 | 25 | 30 −39% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
